AR and prostate carcinoma: Considering those pathways beyond the UPR, RNA-seq analyses demonstrated that treatment with NXP800 impacted other key pathways, including AR, MYC, and E2F activity, implicated in prostate cancer treatment resistance (63, 66, 73).